

Drug and Therapeutics Committee – Minutes –approved

Date / Time	12 th November 2015
Venue	The Board Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Wendy Hornsby, Senior Pharmacy Technician.
Quorate: Yes / No	Yes

Attendance	Mr S Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services Mr P O'Brien, Deputy Chief Pharmacist Prof M Lind, Vice Chair, Professor of Oncology Dr O Ogunbambi, Consultant Rheumatologist Mr K McCorry, Pharmaceutical Advisor, ER CSU Mrs C Grantham, Medicines Management Nurse Dr H Klonin, Consultant Paediatrician (until 9am) Dr E Williamson, Consultant Microbiologist Mr D Cross, Pre-Registration Pharmacist (Guest)
Apologies	Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mrs J Lyon, Head of Medicines Management, North Yorks and Humber CSU

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2015.11.01	Apologies	As above.					
2015.11.02	Declarations of Interest	AM informed the committee that in relation to the 3 new inhaler requests he has given several presentations for different drug companies including Astra Zeneca, Pfizer and Boehringer Ingelheim relating to COPD. He had attended several lunch time meetings, with sandwiches provided by the drug companies. AM also informed the committee that he had received a research grant from Astra Zeneca. ML informed the committee that he had attended an advisory board regarding nintedanib approx. 1 year ago.	Noted	No further action			11/15
2015.11.03	Minutes of the previous meeting	The minutes were accepted as a true record.	Noted	No further action			11/15
2015.11.04	Action Tracker	New Product Request WH had updated the formulary & unlicensed list to include both forms – 0.1% PF minims & 2% unlicensed (canine) ointment Opioid Conversion Chart Awaiting amended version before adding to website. Correspondence Received POB is still trying to source alternative supplier of Disofrol as preparations available do not mirror Disofrol formulation. It was hoped that dexbrompheniramine 2mg tablets were available, but so far none can be sourced. AM has written to patients to inform them of the supply situation. AOB POB has written paper on borderline substances. Paper on agenda for discussion.	Action Complete WH to add to website POB will inform AM once alternative sourced Action Complete	No further action No further action	WH POB	01/16 12/15	11/15 11/15

		New Product Requests ML still to write to Dr Downey re AREDs 2 formulation to check which formulation she would like adding to formulary	ML to write	ML to write	ML	12/15	
		New Product Requests POB and KMcC to discuss Adcal D3 caplet at separate meeting, to agree on best value preparations for HEY and primary care.	Discuss outside of D&T	Discuss & report back to D&TC	POB/KMcC		01/16
		New Product Requests Insulin Glargine – ML has written to Dr Mohammed for clarification of patient cohort.	Action complete	No further action			11/15
		NICE Guidance TA354 & TA355 Edoxaban – has been added to formulary as available on chairs approval.	Action complete	No further action			11/15
		CCG Representation on D&T ML has discussed primary care representation on D&T with AM. New action: AM will write to both Hull and ER CCG and request that a primary care GP representative be appointed to D&T.	AM to write to CCG chairs	AM to write	AM	12/15	
		Correspondence Received Duraphat Toothpaste 5000ppm and fluoride mouthwash have both been added to formulary, with the expectation that HEY will initiate and primary care will continue to prescribe as recommendation is for long term use.	Action complete	No further action			11/15
		Correspondence Received Millinette 20/75 and 30/75 have both been added to formulary.	Action complete	No further action			11/15
		Correspondence Received HEY pharmacy have written and circulated guidance to cover the haloperidol shortage.	Action complete	No further action			11/15
		Ulipristal Ulipristal has been added to HERPC agenda, for discussion in November.	Action complete	No further action			11/15
				No further action			

		AOB Midodrine has been moved from the unlicensed list and added to the formulary.	Action complete		WH		11/15
2015.11.05	New Product Requests	<p>Nintedanib (Vargatef) – Prof M Lind</p> <p>Taflopust & Timolol PF eye drops (Taptiqom) – Mr C Burnett Although the product is significantly more expensive than generic preserved products, there is currently only one formulary combination PF prostaglandin & B-blocker formulation available – Ganfort UDVs. Ophthalmology sought this product as an alternative for patients who did not tolerate bimatoprost in Ganfort. There was discussion about how many patients would require PF products locally, and it was acknowledged that use of combination products would reduce the preservative load to patients' eyes, where they caused sensitivity reactions.</p> <p>Glycopyrronium & indacaterol (Ultibro Breezehaler) – Dr J Morjaria Indacaterol was already formulary, glycopyrronium was not.</p> <p>Tiotropium & olodaterol (Spiolto Respimat) – Dr S Faruqi Tiotropium was already formulary, olodaterol was not.</p> <p>Aclidinium & formoterol (Duaklir Genuair) – Dr S Faruqi Both drugs were individually already formulary, so this was a line extension of them in combination.</p> <p>All three applications were related to the updated HERPC prescribing guideline for COPD. This was discussed and approved.</p> <p>HIV - NHSE Applications</p> <ul style="list-style-type: none"> • Tybost® Cobicistat • Stribild® Elvitegravir/Cobicistat/Emtricitabine/Tenofovir 	<p>Approved in line with NICE TA347.</p> <p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Approved</p> <p>All 3 approved</p>	<p>AM to write to applicant and WH to update formulary</p> <p>KMcC to look at P vs PF usage in primary care.</p> <p>POB to ask Pharmacy MI to find information on patient reactions to preservatives.</p> <p>AM to write to all applicants and WH to update formulary</p>	<p>AM/WH</p> <p>KMcC</p> <p>POB</p> <p>AM/WH</p>	<p>12/15</p> <p>12/15</p> <p>12/15</p> <p>12/15</p>	

		<p>DF</p> <ul style="list-style-type: none"> • Eviplera® Emtricitabine/Tenofovir DF/Rilpivirine <p>All 3 approved, in line with NHS England F03/P/a & F03/P/b recommendations.</p> <p>MDR TB - NHSE Applications</p> <ul style="list-style-type: none"> • Sirturo® Bedaquiline • Delyba® Delamanid <p>Both approved in line with NHS England F04/P/a recommendations.</p>	Both approved				
2015.11.06	NICE Guidance	<p>October 2015</p> <ul style="list-style-type: none"> • NG16 Dementia disability and frailty in later life – mid-life approaches to delay or prevent onset • TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab • TA 362 Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) • TA 358 Tolvaptan for treating autosomal dominant polycystic kidney disease <p>Although tolvaptan is already on formulary for Endocrinology & Oncology use, it was agreed a submission for this new indication was required as this affects a significantly different and larger cohort of patients - funding will need to be discussed.</p> <ul style="list-style-type: none"> • TA 359 Idelalisib for treating chronic lymphocytic leukaemia • TA 360 Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated 	<p>Noted</p> <p>Application to be requested</p> <p>Noted</p> <p>Application to be requested</p> <p>Application to be requested</p> <p>Noted, not recommended</p>	<p>No further action</p> <p>SG to ask SS to prepare application</p> <p>No further action</p> <p>SG to ask ML (covering renal Pharmacist) to ask renal for application</p> <p>SG to ask Dr Allsup & SS to submit application</p> <p>No further action</p>	<p>SG</p> <p>SG</p> <p>SG</p>	<p>12/15</p> <p>12/15</p> <p>12/15</p>	<p>11/15</p> <p>11/15</p> <p>11/15</p>

		<p>metastatic pancreatic cancer</p> <ul style="list-style-type: none"> TA 361 Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) 	Noted, Trust does not currently use preparations in combination with each other	No further action			11/15
2015.11.07	MHRA Drug Safety update October 2015	Mirabegron – risk of severe hypertension and associated cerebrovascular and cardiac events	AM to write to Urology to highlight this issue	AM to write to Urology	AM	12/15	
2015.11.08	Borderline Substance Paper	Paper written due to Trust freedom of information request and MHRA updated guidance on borderline substances. POB has discussed with supplies department and is having further meetings with theatres. It is recommended that D&T review medical devices used for medicinal purposes.	The paper was approved. POB to continue work with theatres.	POB will advise SG what affect this will have on theatres & surgery health group.	POB	01/16	
2015.11.09	Notification of Gifts/Hospitality/ Sponsorship Offered 2014/15	POB informed the committee that Pharmacy had received a freedom of information request regarding gifts/hospitality for the committee. POB informed the committee that the trust had a centrally reporting database where all gifts/hospitality to employees was recorded. Additionally, this information is now being collated by pharmaceutical companies in line with new ABPI rules.	Committee members should continue to follow CP011 and declare gifts/hospitality	AM to write to Liz Thomas	AM	12/15	
2015.11.10	Correspondence Received	Sacubitril valsartan - EAMS 00101/0002 EAMS granted for treatment of heart failure, product will be free until license granted. Afterwards, likely to be expensive and applicable to a large patient group with heart failure, having budget implications for CCGs.	AM to write to Prof Clark to request application, if cardiology wish to use	AM to write to Prof Clark	AM	12/15	

2015.11.12	Chairs Approvals	None this month	Noted	No further action			11/15
2015.11.13	Issues to escalate to OQC	No issues to escalate					11/15
2015.11.14	Any other Business	Propantheline bromide is currently listed on the formulary for use by Gastroenterology only. This restriction is to be removed as also used by Neurology.	Remove restriction	WH to update formulary		12/15	
2015.11.15	Date and Time of Next Meeting	Thursday 10 th December 2015, 8.15am – 9.30am. The Board Room, Alderson House, HRI					